在VKORC1中发生的突变会导致华法林耐药性和多重凝血因子缺陷2型
Simone Rost1, Andreas Fregin, Vytautas Ivaskevicius
1Department of Human Genetics, University of Würzburg, Biozentrum, Am Hubland, 97074 Würzburg, Germany.
Nature
|February 7, 2004
概括
研究人员确定了维生素K环氧化减少酶复合体子单元1 (VKORC1) 基因,该基因对血液凝结和华法林药物功能至关重要. 在VKORC1突变与出血障碍和华法林耐药性有关.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 库马林衍生物,如华法林,对于预防血栓栓塞事件至关重要.
- 这些药物抑制维生素K环氧减少酶 (VKOR) 复合体,对于血液凝固因子合成至关重要.
- VKOR复合物的精确成分仍然难以捉摸,尽管它在VKCFD2和华法林耐药性方面的作用已知.
研究的目的:
- 为了确定维生素K环氧减少酶 (VKOR) 复合物的分子成分.
- 研究2型维生素K依赖性凝血因子 (VKCFD2) 和华法林耐药性 (WR) 联合缺乏的遗传基础.
主要方法:
- 利用三种物种的链接分析来识别候选基因.
- 进行基因测序,以检测受影响个体和动物模型中的突变.
- 进行了涉及过度基因表达的功能测试,以评估酶活性.
主要成果:
- 鉴定了编码维生素K环氧减少酶复合体子单元1 (VKORC1) 的基因,这是一个小的跨膜蛋白.
- 在VKORC1中发现了错误的突变,与人类VKCFD2和抗华法林大鼠相关.
- 野生型VKORC1的过度表达显著增加了VKOR活性,这种活性被华法林抑制.
结论:
- VKORC1是维生素K环氧减少酶复合物的关键组成部分.
- 在VKORC1中发生的突变是VKCFD2的基础,并导致华法林耐药性.
- 这一发现为了解和潜在地治疗凝血障碍和耐药性提供了一个分子标.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Pharmacogenetics of Drug Metabolism: Overview
88
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
88
Venous Thrombosis III: Interprofessional Care
453
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
453
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K


